Page 2019, column 2, section 4, paragraph 2, lines 9-12: The following sentence, which previously read: ''In one trial, [27] patients were enrolled if they had an msSBP of ‡85 mmHg and msDBP of ‡130 mmHg (prehypertension to stage 2 hypertension) at randomization'' has now been corrected as follows:
''In one trial, [27] patients were enrolled if they had an msDBP of ‡85 mmHg and msSBP of ‡130 mmHg (prehypertension to stage 2 hypertension) at randomization'' Page 2025, column 1, In Special Populations section, paragraph 3, lines 4-9: The following sentence, which previously read: ''Greater reductions in msDBP and msSBP were observed with aliskiren 150 or 300 mg/day than with irbesartan 150 or 300 mg/day, with a significantly (p < 0.05) greater proportion of aliskiren recipients achieving BP control than ramipril recipients.
[27] '' has now been corrected as follows:
''Greater reductions in msDBP and msSBP were observed with aliskiren 150 or 300 mg/day than with irbesartan 150 or 300 mg/day, with a significantly (p < 0.05) greater proportion of aliskiren recipients achieving BP control than irbesartan recipients.
[27] ''
Note
All online versions of this article have been updated to reflect these corrections. 
